CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the next-gen thrombotic disease asset SRSD107. That drug, Sirius’ lead ...

The Vallabh/Minikel lab at the Broad Institute has selected Argonaut Manufacturing Services, Inc., “Argonaut,” as the drug product manufacturer for a therape ...